Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Livionex is a proprietary formulation based on the active compound edathamil (EDTA), developed as a metal ion chelator for multiple therapeutic applications. Its mechanism centers on modulating metal ions involved in disease pathways—specifically targeting inflammation, biofilm formation, and lipid-protein aggregates. In oral care (as LIVFRESH/Livionex dental gel), it disrupts dental biofilm by chelating calcium within the plaque matrix to prevent its adhesion and maturation. In ophthalmology (as C-KAD eye drop), it is being developed as a 2.6% EDTA ophthalmic solution to treat early-to-moderate cataracts by penetrating the lens and reducing clouding through chelation of lens-bound metals that contribute to opacification. The technology platform has also been explored for dermatological uses such as treating lower leg edema and stasis dermatitis associated with chronic venous insufficiency[1][3][4][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on livionex.